Laurent Chardonnet is Chief Financial Officer of Prelude Therapeutics Inc. Currently has a direct ownership of 42,165 shares of PRLD, which is worth approximately $50,598. The most recent transaction as insider was on May 23, 2023, when has been sold 5,000 shares (Common Stock) at a price of $5.5 per share, resulting in proceeds of $27,500. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 42.2K
0% 3M change
0% 12M change
Total Value Held $50,598

Laurent Chardonnet Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 23 2023
BUY
Open market or private purchase
$27,500 $5.5 p/Share
5,000 Added 10.6%
42,165 Common Stock
Dec 08 2022
BUY
Open market or private purchase
$47,600 $4.76 p/Share
10,000 Added 21.8%
35,873 Common Stock
Jun 01 2022
BUY
Open market or private purchase
$42,300 $4.23 p/Share
10,000 Added 28.99%
24,500 Common Stock
Mar 21 2022
BUY
Grant, award, or other acquisition
$48,815 $7.51 p/Share
6,500 Added 30.95%
14,500 Common Stock
Dec 13 2021
BUY
Grant, award, or other acquisition
$61,400 $12.28 p/Share
5,000 Added 38.46%
8,000 Common Stock

Also insider at

AXLA
Axcella Health Inc. Healthcare
LC

Laurent Chardonnet

Chief Financial Officer
Cambridge, MA

Track Institutional and Insider Activities on PRLD

Follow Prelude Therapeutics Inc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PRLD shares.

Notify only if

Insider Trading

Get notified when an Prelude Therapeutics Inc insider buys or sells PRLD shares.

Notify only if

News

Receive news related to Prelude Therapeutics Inc

Track Activities on PRLD